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Abstract
Very Low Density Lipoprotein Receptor (VLDLR) and Apolipoprotein E Receptor 2 (ApoER2) are important receptors
in the brain for mediating the signaling effects of the extracellular matrix protein Reelin, affecting neuronal
function in development and in the adult brain. VLDLR and ApoER2 are members of the low density lipoprotein
family, which also mediates the effects of numerous other extracellular ligands, including apolipoprotein E.
Although VLDLR and ApoER2 are highly homologous, they differ in a number of ways, including structural
differences, expression patterns, alternative splicing, and binding of extracellular and intracellular proteins. This
review aims to summarize important aspects of VLDLR and ApoER2 that may account for interesting recent
findings that highlight the unique functions of each receptor.
Introduction
Very Low Density Lipoprotein Receptor (VLDLR) and
Apolipoprotein E Receptor 2 (ApoER2; also known as
LRP8) are members of the LDL receptor family, a group
associated with cellular cholesterol homeostasis [1]. LDL
receptor family members are type I transmembrane recep-
tors and have five highly conserved structural domains: an
extracellular N-terminal ligand-binding domain with
cysteine-rich repeats, an epidermal growth factor (EGF)
domain, an O-linked sugar domain, a single transmem-
brane sequence, and a cytoplasmic domain containing an
NPxY motif. The overall sequence homology between
VLDLR and ApoER2 is around 50% [2].
VLDLR and ApoER2 are primarily recognized for their
role in neural development through Reelin signaling, a
process that is responsible for proper positioning of
newly generated neurons leading to the inside-out forma-
tion of the six-layered neocortex [3]. Reelin is a glycopro-
tein secreted by Cajal-Retzius cells that signals neurons
to migrate radially past earlier-generated cells to arrive at
the appropriate lamina [4]. Reelin signaling is also impor-
tant for alignment of pyramidal neurons in the hippo-
campus and Purkinje cells of the cerebellum [3]. In this
pathway, VLDLR and ApoER2 are cell surface receptors
for Reelin [5,6]. Interaction with Reelin induces VLDLR
and ApoER2 to bind the adaptor protein Dab1 at an
NPxY motif on their cytoplasmic tails [7,8]. Binding of
Dab1 subsequently leads to activation of Src family tyro-
sine kinases (SFKs) and other kinases that phosphorylate
the adaptor protein at its tyrosine residues [9]. VLDLR
and ApoER2 are the exclusive Reelin signaling receptors,
and, consistent with their high extracellular sequence
homology, bind Reelin with similar affinities [10]. Muta-
tions or deletions of the Reelin gene, the Dab1 gene, or
the genes for both VLDLR and ApoER2 result in impro-
per neuronal migration, cortical laminating defects, and
cerebellar hypoplasia [5,7,11,12].
Secreted Reelin can form complexes, including homodi-
mers, which allows association and clustering of multiple
receptors simultaneously [9,13]. This receptor clustering is
necessary for the phosphorylation of Dab1 and its subse-
quent interaction with kinases [9]. Ligand binding to
VLDLR and ApoER2 also initiates clathrin-dependent
receptor endocytosis, which likely modulates further
ligand signaling [14]. Dab1 phosphorylation following
Reelin activation of apoE receptors leads to Dab1 degrada-
tion by proteosomes [15]. Thus, there are several mechan-
isms for regulating the Reelin signaling mechanisms.
Studies of the developing CNS suggest that VLDLR and
ApoER2 serve overlapping functions in controlling neu-
ronal migration. However, several recent studies have
demonstrated clear differences in VLDLR and ApoER2
splicing, localization, interactors, and trafficking. The dif-
ferences in receptor function during development also
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any medium, provided the original work is properly cited.translate into differences in adult brain function. Both
VLDLR and ApoER2 are receptors for apolipoprotein E
(apoE), the leading genetic risk factor for Alzheimer’s dis-
ease (AD) [16], and these receptors may play different
roles in modulating the risk associated with apoE. Here,
we explore VLDLR, ApoER2, and importantly, the
distinctions between them.
Comparison of VLDLR and ApoER2 proteins
Structure
Full length human VLDLR mRNA encodes a protein of
873 amino acids ([17]; NCBI Accession NM_003383.3).
VLDLR has eight cysteine-rich ligand-binding repeats
(LBRs) of approximately 40 amino acids each, an EGF
region with three cysteine rich repeats, a 46 amino acid
O-linked glycosylation domain with numerous threonine
and serine residues, a 22 amino acid transmembrane
domain, and a 54 amino acid cytoplasmic domain con-
taining the NPxY motif (Figure 1) [18]. The first 27
amino acids of the N-terminal are hydrophobic and
serve as the signal peptide. A glycine residue is believed
to constitute the N-terminus of the mature receptor.
There is 97% amino acid identity between VLDLR in
mouse and human [17].
The full length human ApoER2 mRNA encodes a pro-
tein of 870 amino acid residues (NCBI Accession
NM_004631.3). ApoER2 has the same overall domain
structure as VLDLR, with several important differences.
ApoER2 contains a ligand-binding domain of eight LBRs
(only five LBRS are ever observed in the cDNA due to
splicing out of LBRs 4-6; see Figure 1), an EGF domain
with three cysteine-rich repeats, an O-linked glycosyla-
tion domain of 89 amino acids, a transmembrane
domain of 24 amino acids, and a cytoplasmic domain of
115 amino acids (Figure 1) [2].T h es i g n a lp e p t i d ec o n -
sists of approximately 40 amino acids. Homology
between ApoER2 in mouse and human is approximately
90%. In humans, VLDLR and ApoER2 share a roughly
50% primary sequence homology, with the O-linked gly-
cosylation domain (21%) and transmembrane domain
(35%) being the least identical [2].
Thus, the gene sequences of VLDLR and ApoER2 dif-
fer most dramatically in their O-linked glycosylation
domains; this domain in ApoER2 is more than twice the
size of that in VLDLR.
Distribution (Temporal and Spatial)
VLDLR mRNA transcripts are most abundant in brain
with high expression in the heart and skeletal muscle as
well (Table 1). These tissues have relatively high levels
of free lipids, supporting a role of VLDLR in metabolism
of cholesterol and fatty acids [18]. Within the adult
brain, VLDLR mRNA is found in nearly all regions, with
highest expression in the cortex and cerebellum (Table
2). Within these regions, VLDLR is found on microglia
and region-specific pyramidal neurons [19], as well as in
neuroblasts, matrix cells, Cajal-Retzius cells, glioblasts,
astrocytes, and oligodendrocytes [18,20] (Table 3). Sub-
cellularly, VLDLR is in non-lipid raft fractions of cell
membranes [14].
ApoER2 mRNA is present exclusively in CNS, placenta,
and testis [2] (Table 1). Immunohistochemical analysis
reveals ApoER2 expression in the hippocampus, cerebel-
lum, mitral cell layer of the olfactory bulb, neocortex
(cell bodies and dendrites), and cortical neurons [21,22]
(Table 2). In the hippocampus, ApoER2 is found in gran-
ule cells of the dentate gyrus and pyramidal cells of all
CA subfields [21]. In the cerebellum, ApoER2 is found
densely in Purkinje cells [2,21] (Table 3). Subcellularly,
Figure 1 VLDLR and ApoER2 receptors. Specific domains are defined by vertical lines, alternative splice forms are shown with protruding “v"s,
exon numbers are noted, and amino acid %-sequence identities of individual domains are indicated.
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cell membranes [14].
VLDLR and ApoER2 also have different patterns of tis-
sue expression over development (Table 4). At E12 of
development both VLDLR and ApoER2 are expressed at
low levels in the preplate. From E12.5-E13.5, ApoER2 is
expressed in the inner and middle locations of the cor-
t e x ;a n da tE 1 5 ,ApoER2 is in the olfactory bulb and in
medial cortical fields. At E15, VLDLR is seen in the hip-
pocampal anlage-medial cortex, paleocortex, subplate of
the upper cortical plate, and weakly in the neocortical
plate and Cajal-Retzius cells. From E16.5-E17 ApoER2
expression is in the outermost cortex as well as deeper
cerebellar layers, and at E18, ApoER2 is expressed in the
s a m er e g i o n sa sV L D L Rw a sa tE 1 5 ,w i t ht h ee x c e p t i o n
of Cajal-Retzius cells. VLDLR at E18 maintains the same
as its E15 expression pattern but with stronger expres-
sion in Cajal-Retzius cells, and signal in Purkinje cells.
Postnatally, from P0-P6, both VLDLR and ApoER2 are
expressed in the subplate and pyramidal cells of layers
III and V; VLDLR is additionally in Cajal-Retzius and
Purkinje cells postnatally [22,23]. Thus, VLDLR is
expressed earlier in development and is more highly
expressed in Cajal-Retzius cells than ApoER2.
Splicing
Both VLDLR and ApoER2 undergo alternative splicing to
produce several transcript variants. Four transcripts of
VLDLR (I-IV) have been defined [20]. VLDLR-I, lacks
none of the exons, VLDLR-II lacks exon 16 encoding the
O-linked sugar domain, VLDLR-III lacks exon 4 encoding
the third ligand-binding repeat, and VLDLR-IV lacks
both exons 4 and 16. In adult mouse brain, over half
(75%) of transcripts lack exon 16 and the next most com-
mon form lacks both exons 4 and 16. Thus, most of the
VLDLR present in the brain lacks the O-linked sugar
domain and thus would not be expected to be glycosy-
lated. Astrocytes exhibit less splicing of exon 4 and exon
16 than neurons [20]. VLDLR containing exon 16 is
increased in normal aging and Alzheimer’s disease [24].
ApoER2 displays a more complex splicing pattern. Exon
5 (Figure 1), containing ligand-binding repeats 4-6, is
spliced out of all transcripts [21,25]. The eighth LBR is
spliced out during very early stages of development (E12
in mouse). Some transcripts in brain and all transcripts
in placenta contain a 13 amino acid insert containing a
furin cleavage site in place of ligand binding repeat 8
(exon 7) [25]. Exon 9, encoding an EGF repeat, and exon
16, containing the O-linked sugar domain, can be alter-
nately spliced out [21], resulting in a smaller, differen-
tially glycosylated precursor form found in the ER [26].
Splicing of the ligand-binding and EGF repeats alters
binding affinity to ligands, suggesting the different tran-
scripts may function in fine-tuning receptor-ligand inter-
actions [27]. Finally, ApoER2 contains an alternatively
spliced exon (19) that encodes a 59 amino acid domain
in the cytoplasmic tail [2,21,25]. The exon 19 domain is
proline-rich and ends 10 amino acids before the C-termi-
nus of ApoER2. The presence of this domain promotes
interactions of ApoER2 with the c-jun N-terminal kinase
(JNK) interacting proteins, JIP1 and JIP2, and the synap-
tic protein, PSD-95 [28,29] (see below).
Thus, differential splicing of ApoER2 and VLDLR pro-
duce proteins with different numbers of LBRs and very
different cytoplasmic domains.
Interacting proteins
VLDLR and ApoER2 interact with a similar, but not
identical, number of proteins [30]. Extracellularly, these
receptors mediate the effects of specific ligands. Intracel-
lularly, protein interactions alter receptor trafficking and
processing [31]. In addition, proteolytic enzymes act on
the receptors to generate N- and C-terminal fragments
[32,33]. We summarize some of these interacting pro-
teins below (see also Table 5 and Figure 2).
Extracellular Reelin is a large extracellular matrix pro-
tein (~400 kDa) expressed by Cajal-Retzius cells during
embryonic development and by interneurons in the
postnatal brain [3,6]. Reelin can bind to both VLDLR
and ApoER2 in the absence of a co-receptor [6,34],
although a co-receptor may be needed for efficient bind-
ing [35]. Reelin binds to the first ligand binding repeat
of VLDLR and ApoER2; this interaction depends on a
specific lysine residue in Reelin (amino acid 2467) [36].
Reelin is cleaved at numerous sites to generate a series
of fragments [37,38]. Reelin fragments bind equally to
Table 1 Expression of VLDLR and ApoER2 in mouse organs. +/-, +, and ++ represent increasing levels of expression
[2,18]
Brain Heart Testis Ovary Kidney Muscle Placenta Lung Adipose Tissue Small Intestine Liver
VLDLR ++ ++ + + ++ ++ - + + +/- +/-
ApoER2 ++ - ++ +/- - - + - - - -
Table 2 Regional expression of VLDLR and ApoER2
within adult mouse brain
Brain: TH CX ST HI HY CB BR OB SE
VLDLR + + + + + + + - +
ApoER2 - + - + - + - + -
TH = Thalamus, CX = Cerebral Cortex, ST = Striatum, HI = Hippocampus, HY =
Hypothalamus, CB = Cerebellum, BR = Brainstem, OB = Olfactory bulb, SE =
Septum [2,18].
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binds with higher affinity to ApoER2 (LBRs-12378) than
to VLDLR [38]. Reelin fragments with cleaved C-term-
inal regions bind VLDLR and ApoER2 with a signifi-
cantly higher affinity than full-length Reelin [27].
Apolipoprotein E (apoE) is a component of lipoproteins
involved in phospholipid and cholesterol homeostasis
[39]. VLDLR binds and internalizes all human isoforms
of apoE (E2, E3, E4) with high affinity, including lipid-
free forms, and it does so through LBRs 5-8 [39]. The
ApoER2 LBRs binds apoE containing b-VLDL with high
affinity, specifically the ApoER2 splice variants that lack
LBR’s 4-6 and LBR 8 [25]. ApoE bound to receptors may
be internalized and degraded, recycled to the cell surface,
or remain intracellular for extended periods [40]. ApoE
leads to the cleavage of both VLDLR and ApoER2 to gen-
erate secreted forms of these receptors [33].
Thrombospondin and F-spondin are extracellular
matrix proteins. Thrombospondins are a family of tri-
meric or pentameric proteins that are involved in cell-
cell and cell-matrix communication, and affect processes
such as neurite outgrowth, neuronal migration, and
synaptogenesis [41,42]. Thrombospondin-1 binds to the
ligand binding repeats of VLDLR and ApoER2, and com-
petes with Reelin binding [43]. Like Reelin, Thrombos-
pondin can induce Dab1 phosphorylation although not
the subsequent Dab1 degradation [43]. F-spondin is a
secreted molecule whose C-terminal domain is similar to
repeats found in Thrombospondin; its N-terminal
domain is homologous to a domain in Reelin that pro-
motes dimerization [44]. The thrombospondin domain of
F-spondin interacts with the LBR domain of ApoER2
[45] and may bind to both VLDLR and ApoER2 in the
rostral migratory stream [46]. Like Reelin and Thrombos-
pondin, F-spondin can induce activation of Dab1 [47].
Selenium is a ligand for ApoER2 through its transpor-
ter, Selenoprotein P (Sepp1). Sepp1 transports selenium
from the liver to other target tissues such as the testis
and brain [48]. ApoER2 knockout mice have phenotypic
similarities to Sepp1 knockout mice such as lower sele-
nium levels in areas where ApoER2 is normally expressed
(the brain and the testis) [49]. When fed a selenium defi-
cient diet, ApoER2 knockouts had neurological problems,
progressive neurodegeneration, and shortened survival,
similar to Sepp1 knockouts on the same diet [49,50].
ApoER2 mediates the endocytosis of Sepp1 [48].
Membrane Spanning Domain Secretases promote clea-
vage of VLDLR and ApoER2 [32], and these proteolytic
events can be induced by ligand binding [33]. A soluble
extracellular fragment is generated by metalloproteinase
activity; cleavage of ApoER2 occurs at small levels even
when unstimulated, but after Reelin stimulation cleavage
significantly increases [33]. g-secretase cleaves in the
intramembrane regions to generate soluble intracellular
domains [32]. This cleavage was not observed with a
monovalent ligand, the receptor-associated protein RAP,
suggesting the importance of multivalent, clustering-
ligands in this process [9]. ApoE leads to release of extra-
cellular domains and increased accumulation of C-term-
inal fragments of both VLDLR and ApoER2, but with less
cleavage apparent for VLDLR than for ApoER2 [33].
Proteolysis of VLDLR and ApoER2 can also be pro-
moted by extracellular interactions of the receptors with
the proprotein convertase PCSK9 [51]. PCSK9 was first
associated with degradation of the LDL receptor [52],
and is regulated by SREBP [53]. In addition, proteosomal
degradation of VLDLR and ApoER2 can be induced by
an E3 ubiquitin ligase (IDOL, Inducible Degrader of the
LDL Receptor) [54]. IDOL is regulated under the LXR
system [54], which is important for cellular cholesterol
Table 3 Cellular expression of VLDLR and ApoER2 within mouse brain [2,18,21]
Glia Cortical Plate
Neurons
Hippocampal Pyramidal
Neurons
Cajal-Retzius
cells
Olfactory Mitral
Cells
Cerebellar Purkinje
Cells
VLDLR + ++ + ++ - +
ApoER2 - ++ + - ++ ++
Table 4 Temporal and spatial expression of VLDLR and ApoER2 within developing embryonic mouse brain [22,23]
Developmental
day
E12 E12.5-13.5 E15-E15.5 E16.5-E17 E18 P0-P6
VLDLR Low
expression
in preplate
Intermediate
zone and
cortical plate
Developing hippocampus;
palaeocortex; neocortical plate;
Cajal-Retzius cells; subplate; deep
layers of cerebellum
All areas as
E15
All areas as E15, plus:
Stronger expression in
Cajal-Retzius cells;
Purkinje cells
Subplate and pyramidal
cells of layers III and V;
Cajal-Retzius cells;
Purkinje cells
ApoER2 Low
expression
in preplate
Inner and
middle
locations of
cortex
Medial cortical fields; olfactory
bulb; ubiquitously in cerebellum
Outermost
cortex;
deeper
cerebellar
layers
Developing
hippocampus;
palaeocortex;
neocortical plate,
subplate
Subplate and pyramidal
cells of layers III and V
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regulated in sterol-responsive ways, similar to the process
for the LDL receptor.
Intracellular Disabled-1 binds to VLDLR and ApoER2
intracellularly at NPxY motifs through its phosphotyro-
sine-binding (PTB) domain [8]. The PTB domain of
Dab1 contains a hydrophobic groove and this structure
creates the preference for the ApoER2 C-terminal helix
[55]. Dab1 also binds Src and Fyn kinases, which are
important in the downstream organizational effects of
Reelin signaling [56]. The PTB structure has steric inter-
ference with phosphorylated tyrosines, explaining the pre-
ference for the NPxY motifs containing unphosphorylated
tyrosines [55]. The presence of extracellular ligands such
as Reelin increases the interaction of ApoER2 with Dab1
[57,58]. Reelin-binding of VLDLR and ApoER2 result in
similar and robust levels of Dab1 phosphorylation, and
receptor-clustering mimics this effect [26]. Dab1 pro-
motes surface localization of ApoER2 and its subsequent
cleavage by a-secretase [58].
Disabled-2 (Dab2), like its homolog Dab1, is a cytosolic
adaptor protein. Dab2 is found at various locations in the
embryonic mouse CNS throughout development, includ-
ing the developing hindbrain, floor plate of the neural
t u b e ,c h o r o i dp l e x u s ,s u b c o m m i s s u r a lo r g a n ,a n dp i n e a l
g l a n d[ 5 9 ] .L i k eD a b 1 ,D a b 2i st h o u g h tt op l a yar o l ei n
organization and cell positioning by signaling through
LDL receptor family members [60], but it does not com-
pensate for loss of Reelin signaling. Dab2 has been shown
to regulate the MAPK pathway as well as Src activity [61].
Dab2 is also necessary for the internalization of ApoER2;
the PTB domain of Dab2 interacts with the NPxY motif of
ApoER2 and leads to internalization independent of exon
19 [62]. Dab2 does not bind VLDLR [60].
The Pafah1b complex of proteins consists of Lis1
(encoded by the Pafah1b1 gene) and two catalytic a
subunits (encoded by Pafah1b2 and Pafah1b3)[ 6 3 ] .
Heterozygous mutations of Pafah1b1 cause lissencephaly
and a reduced number of cortical gyri, similar to the
reeler phenotype [64]. In vitro, the a-subunits bind
VLDLR at its NPVYL domain but not ApoER2, which
has an NPVYR sequence [65]. Mouse models also sup-
port the conclusion that Pafah1b is functionally con-
nected to VLDLR but not ApoER2 [65].
JIP-1 and JIP-2 act as molecular scaffolds in the JNK-
signaling pathway [66]. JIP-1 and JIP-2 were identified
in a yeast two-hybrid assay as interactors with the alter-
natively-spliced exon 19 of ApoER2, and thus do not
bind VLDLR, which lacks this domain [31]. The PID
domain, rather than the SH3 domain, of JIP-2 was
found to be responsible for the interaction with exon 19
[28]. The binding of JIPs and Dab1 to ApoER2 suggests
that ApoER2 forms a scaffold for various interactors at
the cell surface [28].
PSD-95 is another adaptor protein that interacts pre-
ferentially with exon 19 of ApoER2 [29,31,67]. The first
PDZ (PDZ1) domain of PSD-95 is responsible for the
interaction with the intracellular exon 19 of ApoER2
[67]. PDZ2 of PSD-95 binds the NR2 subunit of NMDA
receptors, possibly responsible for the complexes of
ApoER2, NR2A, and PSD-95 formed in post-synaptic
densities [29].
Table 5 Interactions of various molecules with VLDLR and ApoER2
VLDLR Ectodomain Interactor ApoER2
unknown + Reelin + LBR1
LBR + Thrombospondin F-spondin + LBR
LBR 5-8 + ApoE + LBR 1-3, 7
- selenoprotein + unknown
VLDLR Transmembrane
Interactor
ApoER2
Releases intracellular domains + g-secretase + Releases intracellular domains
Releases extracellular domains + a-secretase + Releases extracellular domains
VLDLR Cytoplasmic Interactor ApoER2
PTB domain binds 14-residue peptide around the
NPxY
+ Dab1 + PTB domain binds 14-residue peptide around the
NPxY
- Dab2 + PTB domain binds NPxY of ApoER2
NPxY followed by leucine + Pafah1b2 & Pafah1b3 - NPxY followed by arginine
- JIP-1, JIP-2 + Exon 19
- PSD-95 + Exon 19
NPxY + FE65 + NPxY
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and one WW domain [68]. FE65 binds to NPxY
sequences in members of the LDL receptor family via
its PTB1 domain [31,69]. FE65 interacts with ApoER2
[31,69] and VLDLR (GWR, unpublished data). The
other domains of FE65 are important for linking apoE
receptors to other proteins, such as the amyloid precur-
sor protein via PTB2 [70], and to the cytoskeleton via
the WW domain, affecting cell movement [71]. Knock-
out of FE65 family members results in lissencephaly
[72], as for several of the other proteins that interact
with apoE receptors (see above).
Unique functions of VLDLR and ApoER2
One of the main differences between VLDLR and
ApoER2 is that ApoER2 is restricted to the brain, testis,
and placenta whereas VLDLR is expressed in tissues
throughout the body. Both receptors are widely
Figure 2 VLDLR and ApoER2 interacting proteins. Some of the extracellular and intracellular proteins that interact with VLDLR and ApoER2
are indicated.
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the adult. Knockout mouse models of only ApoER2 or
only VLDLR do not show the dramatic neuronal migra-
tion defects seen in the mice lacking both receptors, a
phenocopy of Reelin and Dab1 knockouts [5]; this
observation led to the hypothesis that the receptors
have overlapping functions in the brain. However, sev-
eral recent studies have begun to define distinct func-
tions of VLDLR and ApoER2; we will discuss these
distinctions in this section.
Contributions to neuronal migration
Reelin interacts extracellularly with VLDLR and ApoER2,
promoting Dab1 phosphorylation intracellularly, and
resulting in downstream effects that regulate proper
migration of neurons during development [6,34,73]. As
mentioned, double VLDLR/ApoER2 knock-outs show the
full reeler phenotype, similar to animals lacking Reelin or
Dab1 [74]. However, analyses of the single knock-out
mouse models provide insight into different functions of
ApoER2 and VLDLR. Both ApoER2 and VLDLR knock-
outs have smaller, less foliated cerebella, less cortical
lamination, and a splitting of the CA1 layer of the hippo-
campus [5]. However, the cortical and hippocampal
defects were more pronounced in the ApoER2 knock-
outs, and the cerebellar defect was more pronounced in
the VLDLR knock-outs [5].
In addition to these deficits, the VLDLR knock-out
neurons demonstrated greater invasion of migrating cor-
tical neurons into the marginal zone [5,23]. Furthermore,
fate mapping demonstrated that in ApoER2 knock-out
mice, the late-born neurons fail to migrate properly in
the cortex [23]. In VLDLR knockouts, the early-born cells
ended up in an organized layer of the inner cortex (simi-
lar to wild-type animals), suggesting that VLDLR does
not have a substantial effect on the limited migration of
early-born neurons [23]. VLDLR is primarily expressed
in the intermediate zone and the cortical plate adjacent
to Reelin-expressing cells in the marginal zone [5]. These
observations support a hypothesis that VLDLR mediates
an e u r o n a l“stop signal” [23]. In WT mice, ApoER2
receptors are most strongly expressed at E16.5 and E18.5,
the stage when late-born neurons reach the superficial
layers of the outer cortex. In the ApoER2 knock-out, the
early-generated layers formed with minor deficits but
late-generated layers were highly disrupted [23]. Antibo-
dies against molecules of the radial glial scaffold revealed
no abnormal arrangement of the radial glial cells. In
ApoER2 knock-outs there is strong disruption of the
radial alignment of the cortical neurons; this phenotype
is not seen in the VLDLR-deficient cortex in which neu-
rons are distributed radially [5]. Furthermore, neurons in
ApoER2 knock-outs are packed into horizontal layers
while the VLDLR knock-outs do not demonstrate dis-
cernable cortical lamina [5].
Human mutations in the Reelin gene (RELN)g e n e
cause neuronal migration defects, producing alterations
in the architecture of the cortex and cerebellum [75].
The structural phenotype of lissencephaly, malformed
hippocampus, and cerebellar hypoplasia is associated
with a clinical phenotype of hypotonia, ataxia, and
severe mental retardation [75]. Humans have also been
identified with homozygous deletion of the VLDLR gene
[76]. The VLDLR deletion causes a more mild cerebral
gyral simplification, less cerebellar hypoplasia, and unre-
markable changes to the hippocampus, compared with
the RELN mutation [76]. Thus, the observations with
mouse knock-out models support the findings in human
genetic diseases.
Pafah1b effects on neuronal migration via VLDLR
Several of the proteins that interact with VLDLR and
ApoER2 have been identified through mouse knock-out
models that demonstrate effects on neuronal migration.
The lissencephaly phenotype of Pafah1b1 heterozygous
mutants sparked interest in exploring the relationship
between the Pafah1b complex and the Reelin pathway,
including the VLDLR and ApoER2 receptors [64]. The
Pafah1b1
+/-;ApoER2
-/- double mutants had severe deficits
in the forebrain, including inversion of cortical-lamina
and hypercellularity of layer I similar to the reeler-like
phenotype of an ApoER2;VLDLR double knock-out.
However, Pafah1b1
+/-;VLDLR
-/- double mutants were
mostly normal. The Pafah1b1
+/-;ApoER2
-/- mutants still
underwent Dab1 phosphorylation when stimulated with
Reelin (unlike in reeler mice), demonstrating that signal-
ing was still intact (via VLDLR) but was not enough for
proper cortical layer formation (requiring Lis1). The a-
subunits serve as adapter-molecules by bringing Lis1 to
VLDLR; one of the subunits (a2) binds to Dab1 [77]. The
intact signaling suggests Lis1 is downstream of VLDLR
and SRKs [65]. In humans, deletions and duplications of
the PAFAH1B1 also result in neuronal migration defects,
leading to a reduction in the number of cortical gyri
[63,78,79]. Like the human VLDLR homozygous deletion
[76], the PAFAH1B1 heterozygous deletion causes a
somewhat milder phenotype than RELN mutations [75].
Thus, the Pafah1b complex mediates downstream effects
of VLDLR on neuronal migration, but is not necessary
for the function of ApoER2.
Lipid-raft sorting
Lipoprotein receptors are associated with clathrin-coated
pits, indicative of a role in ligand endocytosis and degra-
dation. However, ApoER2 is only found in caveolae-rich
membrane fractions [26,80], distinguishing it from the
non-lipid-raft VLDLR. Caveolae are a type of lipid raft
primarily involved in signaling pathways [80]. Chimeric
ApoER2 constructs containing only its cytoplasmic tail
do not associate into rafts, suggesting it is the trans-
membrane or ectodomain involved in the sorting [26].
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Page 7 of 10The transmembrane domain of ApoER2 has only 33%
sequence identity compared with VLDLR (Figure 1); this
low level of homology may be related to differential
sorting of ApoER2 into lipid rafts.
Thus, the different localization of ApoER2 and VLDLR
may play a role in their different functions. Reelin is endo-
cytosed via clathrin-coated vesicles and degraded by
VLDLR much more efficiently than by ApoER2 [14]. In
cell culture experiments, VLDLR facilitated degradation of
more than 60% of bound Reelin after 12 minutes, and all
of Reelin by 24 minutes. With ApoER2, after 24 minutes
~75% of Reelin remained associated with the cells [14].
Disruption of raft structures increased ApoER2-mediated
Reelin endocytosis to the rate of VLDLR, indicating that
ApoER2’s localization in rafts results in reduced endocyto-
sis. Reelin-binding resulted in a lysosomal (rather than
proteosomal) degradation of ApoER2 but not of VLDLR,
independent of raft-association [14]. However, ApoER2
bound by the non-clustering ligand RAP (receptor-asso-
ciated protein) did not result in down regulation, suggest-
ing that degradation is mediated by receptor clustering
[14]. Thus, ApoER2 may be more important for the med-
iation of Reelin signaling in lipid rafts, and VLDLR may be
more important for the intracellular degradation of Reelin.
Neuronal signaling
Activation of ApoE receptors directly promotes signal
cascades involving the intracellular adaptor protein Dab1,
increased activation of SFKs, and decreased activation of
JNK [81]. Indirect activation of signaling involving cal-
cium-mediated signal transduction pathways occurs
through modification and subsequent increase in
NMDAR conductance, which in turn can activate the
extracellular signal-related kinases 1/2 (ERK1/2) [29,82].
It is unclear what the specific contributions are for each
ApoE receptor or ligand; however, the use of the ligand
Reelin has allowed for the identification of at least three
specific pathways associated with ApoER2 and VLDLR
activation. First, acute Reelin application to hippocampal
slices results in NMDA receptor phosphorylation of both
NR2A and NR2B subunits that is dependent on Src acti-
vation [28,29,67]. Second, chronic Reelin treatment of
cultured hippocampal neurons shows a significant
decrease in the number of silent synapses by increasing
AMPA receptor insertion at synaptic terminals that is
dependent on PI3K signaling [83]. Third, ApoE receptors
affect the activation state on JNK through unstudied
mechanisms [28,29,67]. JNK-interacting proteins JIP-1
and JIP-2 interact with exon 19 of ApoER2 [28,29,67],
potentially affecting JNK signaling in many processes
such as cell proliferation, morphogenesis and apoptosis
[66]. In general, the interactions with exon 19 and conse-
quent downstream signaling effects may explain some of
the differences observed between ApoER2 and VLDLR.
PSD-95 could act as a link between ApoER2 and NMDA
receptors since the PDZ1 domain of PSD-95 binds
ApoER2 and the PDZ2 domain of PSD-95 binds NMDA
receptor subunits [67]. Thus, the formation of multimeric
complexes of signaling proteins with ApoER2 may med-
iate specific signal transduction mechanisms.
Analysis of ApoER2 and VLDLR knockout mice demon-
strate that there are differential contributions of VLDLR
and ApoER2 to hippocampal synaptic plasticity. Mice defi-
cient for ApoER2 have a greater deficit in hippocampal
area CA1 long-term potentiation (LTP) compared to
VLDLR deficient mice, in particular when a theta-burst
high frequency stimulation protocol is used [82]. The
addition of Reelin can enhance LTP, but this requires the
presence of both receptors [29,82]. This dual receptor
dependency may reflect the necessity for the activation of
signal transduction pathways from both receptors
(described above) or the need for ApoER2/VLDLR cluster-
ing during Reelin binding. Nevertheless, current experi-
mental evidence suggests that ApoER2 plays a signaling
role independent of VLDLR. For example, the in vitro
increase in LTP in the presence of Reelin requires interac-
tion between ApoER2 and NMDA receptors through exon
19 of ApoER2 [28,29,67]. ApoER2 knockout mice or mice
lacking exon 19 of ApoER2 show no Reelin-dependent
changes in NMDARs or increase in LTP induction.
Conclusions
VLDLR and ApoER2 have homologous extracellular and
intracellular domains and each is important for Reelin-
mediated neuronal migration that depends on Dab1. Both
undergo a series of proteolytic events that result in soluble
forms of the receptors and intracellular domains, and that
regulate active receptor levels. However, VLDLR and
ApoER2 also interact with different ligands that define
separate roles for these receptors in various signaling path-
ways. VLDLR has a broader tissue distribution and inter-
acts specifically with the Pafah1b complex. ApoER2 is
found in lipid rafts and interacts with PSD-95 and JIPs
through a unique alternatively spliced sequence. These
interactions affect signaling pathways regulated by intra-
cellular calcium levels and JNK. As we continue to exam-
ine these receptors, we will better define their unique roles
in neuronal migration and synaptic signaling.
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